Off-label prescribing for allergic diseases in children

World Allergy Organization Journal

Volumn 7, Issue 1, 2014, Pages

  Silva, Diana ^a,b   Ansotegui, Ignacio ^c   Morais Almeida, Mário ^b,d  

^a Centro Hospitalar Universitário de São João   (Portugal)

^b CUF Descobertas Hospital   (Portugal)

^c HOSPITAL QUIRÓN   (Spain)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

Anti asthmatic agents; Asthma; Atopic dermatitis; Child; Drugs; Off label use; Preschool child; Rhinitis; Unlicensed; Urticaria

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID DERIVATIVE; PRESCRIPTION DRUG;

ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; AWARENESS; CHILD; CHILDHOOD DISEASE; CLINICAL PRACTICE; HUMAN; LONG TERM CARE; OFF LABEL DRUG USE; PRESCRIPTION; REVIEW; SYSTEMATIC REVIEW (TOPIC); URTICARIA;

EID: 84910674375     PISSN: None     EISSN: 19394551     Source Type: Journal    
DOI: 10.1186/1939-4551-7-4     Document Type: Review

References (82)

1. The European Regulation on medicines for paediatric use. J Dunne, Paediatr Respir Rev 2007 8 177 183 10.1016/j.prrv.2007.04.004 17574163
2. Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years. A Ceci, M Felisi, P Baiardi, F Bonifazi, M Catapano, C Giaquinto, A Nicolosi, M Sturkenboom, A Neubert, I Wong, Eur J Clin Pharmacol 2006 62 947 952 10.1007/s00228-006-0193-0 17021892
3. Stimulation programs for pediatric drug research-do children really benefit? I Boots, RN Sukhai, RH Klein, RA Holl, JM Wit, AF Cohen, J Burggraaf, Eur J Pediatr 2007 166 849 855 10.1007/s00431-006-0381-z 17225950
4. The status of paediatric medicines initiatives around the world - What has happened and what has not? K Hoppu, G Anabwani, F Garcia-Bournissen, M Gazarian, GL Kearns, H Nakamura, RG Peterson, S Sri Ranganathan, SN de Wildt, Eur J Clin Pharmacol 2012 68 1 10 10.1007/s00228-011-1089-1 21732178
5. Clinical Investigation of Medicinal products in the pediatric population http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E11/Step4/E11-Guideline.pdf
6. Pediatric Research Equity Act of 2003 http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM077853.pdf
7. Best Pharmaceuticals for Children Act http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ucm148011.htm
8. Regulation (EC) number 1901/2006 of the European parliament and of the council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 http://ec.europa.eu/health/files/eudralex/vol-1/reg-2006-1901/reg-2006-1901-en.pdf
9. 4th WHO Model List of Essential Medicines for Children's (April 2013) http://www.who.int/medicines/publications/essentialmedicines/en/index.html
10. Report from the commission to the European Parliament and the Council, Better Medicines for Children-From Concept to Reality; General Report on experience acquired as a result of the application of Regulation (EC) No 1901/2006 on medicinal products for paediatric use. [ http://ec.europa.eu/health/files/paediatrics/2013-com443/paediatric-report-com(2013)443-en.pdf ]
11. Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. J Mason, M Pirmohamed, T Nunn, Eur J Clin Pharmacol 2012 68 21 28 10.1007/s00228-011-1097-1 21779968
12. Off-label prescribing for allergic diseases in pre-school children. M Morais-Almeida, AJ Cabral, Allergol Immunopathol (Madr) 2013 http://dx.doi.org/10.1016/j.aller.2013.02.011
13. Off-label use of medicines: consensus recommendations for evaluating appropriateness. M Gazarian, M Kelly, JR McPhee, LV Graudins, RL Ward, TJ Campbell, Med J Aust 2006 185 544 548 17115966
14. Defining off-label and unlicensed use of medicines for children: results of a Delphi survey. A Neubert, IC Wong, A Bonifazi, M Catapano, M Felisi, P Baiardi, C Giaquinto, CA Knibbe, MC Sturkenboom, MA Ghaleb, A Ceci, Pharmacol Res 2008 58 316 322 10.1016/j.phrs.2008.09.007 18852048
15. Drug use in children: cohort study in three European countries. MC Sturkenboom, KM Verhamme, A Nicolosi, ML Murray, A Neubert, D Caudri, G Picelli, EF Sen, C Giaquinto, L Cantarutti, et al. BMJ 2008 337 2245 10.1136/bmj.a2245 19029175
16. A literature review on off-label drug use in children. C Pandolfini, M Bonati, Eur J Pediatr 2005 164 552 558 10.1007/s00431-005-1698-8 15912383
17. Off-label medicine use in children and adolescents: results of a population-based study in Germany. H Knopf, IK Wolf, G Sarganas, W Zhuang, W Rascher, A Neubert, BMC Public Health 2013 13 631 10.1186/1471-2458-13-631 23822744
18. Off-label drug prescribing in a Portuguese paediatric emergency unit. M Ribeiro, A Jorge, AF Macedo, Int J Clin Pharm 2013 35 30 36 10.1007/s11096-012-9699-y 23054136
19. Off-label use of medicines in paediatric inpatients at an Australian teaching hospital. CD Ballard, GM Peterson, AJ Thompson, SA Beggs, J Paediatr Child Health 2013 49 38 42 10.1111/jpc.12065 23279160
20. Paediatric drug use with focus on off-label prescriptions at Swedish hospitals-a nationwide study. E Kimland, P Nydert, V Odlind, Y Bottiger, S Lindemalm, Acta Paediatr 2012 101 772 778 10.1111/j.1651-2227.2012.02656.x 22404126
21. Unlicensed and off-label drug use in hospitalized children in Croatia: a cross-sectional survey. G Palcevski, N Skocibusic, V Vlahovic-Palcevski, Eur J Clin Pharmacol 2012 68 1073 1077 10.1007/s00228-012-1221-x 22307225
22. Paediatric drug use with focus on off-label prescriptions in Swedish outpatient care-a nationwide study. J Olsson, E Kimland, S Pettersson, V Odlind, Acta Paediatr 2011 100 1272 1275 10.1111/j.1651-2227.2011.02287.x 21438922
23. Off-label and unlicensed medication use and associated adverse drug events in a pediatric emergency department. H Phan, M Leder, M Fishley, M Moeller, M Nahata, Pediatr Emerg Care 2010 26 424 430 10.1097/PEC.0b013e3181e057e1 20502385
24. Drug utilization and off-label drug use among Spanish emergency room paediatric patients. C Morales-Carpi, L Estan, E Rubio, E Lurbe, FJ Morales-Olivas, Eur J Clin Pharmacol 2010 66 315 320 10.1007/s00228-009-0747-z 19936729
25. Off-label use of prescription drugs in childhood and adolescence: an analysis of prescription patterns in Germany. B Muhlbauer, K Janhsen, J Pichler, P Schoettler, Dtsch Arztebl Int 2009 106 25 31 19564959
26. Off-label prescribing to children in the United States outpatient setting. AT Bazzano, R Mangione-Smith, M Schonlau, MJ Suttorp, RH Brook, Acad Pediatr 2009 9 81 88 10.1016/j.acap.2008.11.010 19329098
27. Off-label drug use in children. SS Jain, SB Bavdekar, NJ Gogtay, PA Sadawarte, Indian J Pediatr 2008 75 1133 1136 10.1007/s12098-008-0188-1 18810340
28. Off-label drug use among hospitalised children: identifying areas with the highest need for research. L Hsien, A Breddemann, AK Frobel, A Heusch, KG Schmidt, S Laer, Pharm World Sci 2008 30 497 502 10.1007/s11096-008-9193-8 18219585
29. Off-label drug use in hospitalized children. SS Shah, M Hall, DM Goodman, P Feuer, V Sharma, C Fargason Jr, D Hyman, K Jenkins, ML White, FH Levy, et al. Arch Pediatr Adolesc Med 2007 161 282 290 10.1001/archpedi.161.3.282 17339510
30. Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden. M Ufer, E Kimland, U Bergman, Pharmacoepidemiol Drug Saf 2004 13 147 152 10.1002/pds.858 15072113
31. Risk factors for unlicensed and off-label drug use in children outside the hospital. LT de Jong-van Den Berg, E Schirm, H Tobi, Pediatrics 2003 111 291 295 10.1542/peds.111.2.291 12563053
32. Off-label use of drugs in Italy: a prospective, observational and multicentre study. C Pandolfini, P Impicciatore, D Provasi, F Rocchi, R Campi, M Bonati, Acta Paediatr 2002 91 339 347 10.1111/j.1651-2227.2002.tb01726.x 12022310
33. Unlicensed and off label prescribing of drugs in general practice. J McIntyre, S Conroy, A Avery, H Corns, I Choonara, Arch Dis Child 2000 83 498 501 10.1136/adc.83.6.498 11087285
34. Off label prescribing to children in primary care in Germany: retrospective cohort study. R Bucheler, M Schwab, K Morike, B Kalchthaler, H Mohr, H Schroder, P Schwoerer, CH Gleiter, BMJ 2002 324 1311 1312 10.1136/bmj.324.7349.1311 12039825
35. Off-label prescribing to children in primary care: retrospective observational study. S Ekins-Daukes, PJ Helms, CR Simpson, MW Taylor, JS McLay, Eur J Clin Pharmacol 2004 60 349 353 15146302
36. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. L Lindell-Osuagwu, MJ Korhonen, S Saano, M Helin-Tanninen, T Naaranlahti, H Kokki, J Clin Pharm Ther 2009 34 277 287 10.1111/j.1365-2710.2008.01005.x 19650250
37. Extent and nature of unlicensed and off-label medicine use in hospitalised children in Palestine. MR Khdour, HO Hallak, KS Alayasa, QN AlShahed, AF Hawwa, JC McElnay, Int J Clin Pharm 2011 33 650 655 10.1007/s11096-011-9520-3 21567279
38. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. A Neubert, H Dormann, J Weiss, T Egger, M Criegee-Rieck, W Rascher, K Brune, B Hinz, Drug Saf 2004 27 1059 1067 10.2165/00002018-200427130-00006 15471510
39. Drug utilization study in pediatric prescriptions of a university hospital in southern Brazil: off-label, unlicensed and high-alert medications. L Dos Santos, I Heineck, Farm Hosp 2012 36 180 186 10.1016/j.farma.2010.12.008 22030161
40. Off label use of prescription medicines in children in outpatient setting in Estonia is common. J Lass, A Irs, H Pisarev, T Leinemann, I Lutsar, Pharmacoepidemiol Drug Saf 2011 20 474 481 10.1002/pds.2125 21416552
41. Use of unlabelled and off licence drugs in children. Use of unlicensed drugs may be recommended in guidelines. FA Riordan, BMJ 2000 320 1210 10.1136/bmj.320.7243.1210
42. Prescribing of medicines in the Danish paediatric population outwith the licensed age group: characteristics of adverse drug reactions. L Aagaard, EH Hansen, Br J Clin Pharmacol 2011 71 751 757 10.1111/j.1365-2125.2011.03915.x 21241353
43. Adverse drug reactions and off-label drug use in paediatric outpatients. B Horen, JL Montastruc, M Lapeyre-Mestre, Br J Clin Pharmacol 2002 54 665 670 10.1046/j.1365-2125.2002.t01-3-01689.x 12492616
44. Off-label, off-limits? Parental awareness and attitudes towards off-label use in paediatrics. C Lenk, P Koch, H Zappel, C Wiesemann, Eur J Pediatr 2009 168 1473 1478 10.1007/s00431-009-0956-6 19277709
45. Trends of outpatient prescription drug utilization in US children, 2002-2010. G Chai, L Governale, AW McMahon, JP Trinidad, J Staffa, D Murphy, Pediatrics 2012 130 23 31 10.1542/peds.2011-2879 22711728
46. Unlicensed and off-label prescription of respiratory drugs to children. GW t'Jong, IA Eland, MC Sturkenboom, JN van den Anker, BH Strickerf, Eur Respir J 2004 23 310 313 10.1183/09031936.04.00015404 14979509
47. Autoridade Nacional do Medicamento e Produtos de Saúde http://www.infarmed.pt/infomed/pesquisa.php
48. FDA Approved Drug Products http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
49. Global Strategy for Asthma Management and Prevention. [ http://www.ginasthma.org ]
50. National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma http://www.ncbi.nlm.nih.gov/books/NBK7232/
51. Promoting appropriate use of drugs in children. VN Yewale, D Dharmapalan, Int J Pediatr 2012 2012 906570 22645620
52. Respiratory medicines for children: current evidence, unlicensed use and research priorities. AR Smyth, A Barbato, N Beydon, H Bisgaard, K de Boeck, P Brand, A Bush, B Fauroux, J de Jongste, M Korppi, et al. Eur Respir J 2010 35 247 265 10.1183/09031936.00139508 19840958
53. Medication use in children with asthma: not a child size problem. C Grover, C Armour, PP Asperen, R Moles, B Saini, J Asthma 2011 48 1085 1103 10.3109/02770903.2011.624234 22013989
54. Global Strategy for the Diagnosis and Management of Asthma in Children 5 Years and Younger. GINA, Book Global Strategy for the Diagnosis and Management of Asthma in Children 5 Years and Younger City, Editor ed., 2009
55. Global strategy for the diagnosis and management of asthma in children 5 years and younger. SE Pedersen, SS Hurd, RF Lemanske Jr, A Becker, HJ Zar, PD Sly, M Soto-Quiroz, G Wong, ED Bateman, Pediatr Pulmonol 2011 46 1 17 20963782
56. Assessment of pediatric asthma drug use in three European countries; a TEDDY study. EF Sen, KM Verhamme, A Neubert, Y Hsia, M Murray, M Felisi, C Giaquinto, GW t' Jong, G Picelli, E Baraldi, et al. Eur J Pediatr 2011 170 81 92 10.1007/s00431-010-1275-7 20811908
57. In-label and off-label use of respiratory drugs in the Italian paediatric population. P Baiardi, A Ceci, M Felisi, L Cantarutti, S Girotto, M Sturkenboom, E Baraldi, Acta Paediatr 2010 99 544 549 10.1111/j.1651-2227.2009.01668.x 20105140
58. Healthcare professional experiences and attitudes on unlicensed/off-label paediatric prescribing and paediatric clinical trials. T Mukattash, AF Hawwa, K Trew, JC McElnay, Eur J Clin Pharmacol 2011 67 449 461 10.1007/s00228-010-0978-z 21243345
59. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). J Bousquet, N Khaltaev, AA Cruz, J Denburg, WJ Fokkens, A Togias, T Zuberbier, CE Baena-Cagnani, GW Canonica, C van Weel, et al. Allergy 2008 63 Suppl 86 8 160 18331513
60. The diagnosis and management of rhinitis: an updated practice parameter. DV Wallace, MS Dykewicz, DI Bernstein, J Blessing-Moore, L Cox, DA Khan, DM Lang, RA Nicklas, J Oppenheimer, JM Portnoy, et al. J Allergy Clin Immunol 2008 122 1 84 10.1016/j.jaci.2008.06.003 18662584
61. BSACI guidelines for the management of allergic and non-allergic rhinitis. GK Scadding, SR Durham, R Mirakian, NS Jones, SC Leech, S Farooque, D Ryan, SM Walker, AT Clark, TA Dixon, et al. Clin Exp Allergy 2008 38 19 42 18081563
62. Evidence for clinical safety, efficacy, and parent and physician perceptions of levocetirizine for the treatment of children with allergic disease. AN Pampura, NG Papadopoulos, V Spicak, R Kurzawa, Int Arch Allergy Immunol 2011 155 367 378 10.1159/000321181 21346367
63. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. JL Brozek, J Bousquet, CE Baena-Cagnani, S Bonini, GW Canonica, TB Casale, RG van Wijk, K Ohta, T Zuberbier, HJ Schunemann, J Allergy Clin Immunol 2010 126 466 476 10.1016/j.jaci.2010.06.047 20816182
64. Joint meeting on the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4323b1-02-FDA.pdf
65. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. Early Treatment of the Atopic Child. FE Simons, J Allergy Clin Immunol 1999 104 433 440 10.1016/S0091-6749(99)70389-1 10452767
66. Safety of cetirizine in infants 6 to 11 months of age: a randomized, double-blind, placebo-controlled study. FE Simons, P Silas, JM Portnoy, J Catuogno, D Chapman, AO Olufade, Pharmd, J Allergy Clin Immunol 2003 111 1244 1248 10.1067/mai.2003.1496 12789224
67. Safety of levocetirizine treatment in young atopic children: An 18-month study. FE Simons, Pediatr Allergy Immunol 2007 18 535 542 10.1111/j.1399-3038.2007.00558.x 17561929
68. Prophylactic management of children at risk for recurrent upper respiratory infections: the Preventia I Study. A Grimfeld, ST Holgate, GW Canonica, S Bonini, MP Borres, D Adam, C Canseco Gonzalez, P Lobaton, P Patel, A Szczeklik, et al. Clin Exp Allergy 2004 34 1665 1672 10.1111/j.1365-2222.2004.02098.x 15544588
69. New oral H1 antihistamines in children: facts and unmeet needs. FM de Benedictis, D de Benedictis, GW Canonica, Allergy 2008 63 1395 1404 10.1111/j.1398-9995.2008.01771.x 18782118
70. Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. SK Gupta, B Kantesaria, C Banfield, Z Wang, Br J Clin Pharmacol 2007 64 174 184 10.1111/j.1365-2125.2007.02859.x 17324243
71. A control model to evaluate pharmacotherapy for allergic rhinitis in children. G Rachelefsky, JR Farrar, JAMA Pediatr 2013 167 380 386 10.1001/jamapediatrics.2013.623 23440263
72. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. T Zuberbier, R Asero, C Bindslev-Jensen, G Walter Canonica, MK Church, AM Gimenez-Arnau, CE Grattan, A Kapp, M Maurer, HF Merk, et al. Allergy 2009 64 1427 1443 10.1111/j.1398-9995.2009.02178.x 19772513
73. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. K Krause, A Spohr, T Zuberbier, MK Church, M Maurer, Allergy 2013 68 921 928 10.1111/all.12171 23742030
74. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. F Siebenhaar, F Degener, T Zuberbier, P Martus, M Maurer, J Allergy Clin Immunol 2009 123 672 679 10.1016/j.jaci.2008.12.008 19201016
75. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Ring, A Alomar, T Bieber, M Deleuran, A Fink-Wagner, C Gelmetti, U Gieler, J Lipozencic, T Luger, AP Oranje, et al. J Eur Acad Dermatol Venereol 2012 26 1045 1060 10.1111/j.1468-3083.2012.04635.x 22805051
76. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Ring, A Alomar, T Bieber, M Deleuran, A Fink-Wagner, C Gelmetti, U Gieler, J Lipozencic, T Luger, AP Oranje, et al. J Eur Acad Dermatol Venereol 2012 26 1176 1193 10.1111/j.1468-3083.2012.04636.x 22813359
77. Atopic dermatitis: a practice parameter update 2012. L Schneider, S Tilles, P Lio, M Boguniewicz, L Beck, J LeBovidge, N Novak, D Bernstein, J Blessing-Moore, D Khan, et al. J Allergy Clin Immunol 2013 131 295 299 e291-227 10.1016/j.jaci.2012.12.672 23374261
78. Adverse effects of topical glucocorticosteroids. UR Hengge, T Ruzicka, RA Schwartz, MJ Cork, J Am Acad Dermatol 2006 54 1 15 quiz 16-18 10.1016/j.jaad.2005.01.010 16384751
79. Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate. U Blume-Peytavi, U Wahn, J Eur Acad Dermatol Venereol 2011 25 508 515 10.1111/j.1468-3083.2010.03942.x 21492244
80. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. WW Carr, Paediatr Drugs 2013 15 303 310 10.1007/s40272-013-0013-9 23549982
81. Medicines: medicines for children, Fact sheet N°341 http://www.who.int/mediacentre/factsheets/fs341/en/
82. Pediatric off-label drug use in China: risk factors and management strategies. L Zhang, Y Li, Y Liu, L Zeng, D Hu, L Huang, M Chen, J Lv, C Yang, J Evid Based Med 2013 6 4 18 10.1111/jebm.12017 23557523